Filing Overview
Filing: Form 10-K for the fiscal year ended December 31, 2014, filed February 27, 2015. The provided filing identifies the registrant as Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.; this entity mismatch should be verified.
Business Context and Reporting Period
Zeta Acquisition Corp. II was a Delaware blank-check, shell, and development-stage company formed to identify and complete a business combination. It had not identified a target, entered negotiations, or conducted active operating activities through December 31, 2014. The company had no employees other than its officers and directors, no owned or leased property, and no publicly traded market for its common stock.
The company reported 5,000,000 common shares outstanding as of February 27, 2015. Management owned 80% of the outstanding shares. No preferred shares were issued.
Financial Metrics
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $(30,799) | $(28,701) |
| Loss per basic and diluted share | $(0.01) | $(0.01) |
| Net cash used in operating activities | $(16,020) | $(23,324) |
| Net cash provided by financing activities | $15,000 | $25,000 |
| Cash and cash equivalents at year-end | $5,263 | $6,283 |
| Total assets | $5,263 | $8,783 |
| Total liabilities | $160,304 | $133,025 |
| Stockholders’ deficit | $(155,041) | $(124,242) |
The company generated no revenue since inception. The 2014 net loss consisted primarily of general and administrative expenses of $23,972 and interest expense of $6,827. No meaningful operating margin is applicable because the company had no revenue.
Year-end liabilities included $125,000 of notes payable to stockholders, $24,002 of accrued interest, $8,900 of accrued expenses, and $2,402 of accounts payable. Stockholder notes were unsecured, bore interest at 6%, and were due on demand.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $2,098, or approximately 7%, from $28,701 in 2013 to $30,799 in 2014.
- Operating cash use improved by $7,304, from $23,324 to $16,020.
- Financing proceeds declined by $10,000, from $25,000 to $15,000; all 2014 financing proceeds were stockholder loans.
- Cash declined by $1,020, from $6,283 to $5,263, and prepaid expenses declined from $2,500 to zero.
- Total liabilities increased by $27,279, primarily reflecting additional stockholder borrowings, accrued interest, and accrued expenses.
- Accumulated deficit increased to $205,041 from $174,242.
Guidance, Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate during the following 12 months. It had no definitive agreement or active discussions with a target as of the filing date and provided no financial or transaction guidance.
Management stated that the company may not be able to satisfy its cash requirements for the next 12 months. Continued operations depend on future financing, related-party advances, profitable operations, and ultimately locating a suitable target and completing a potential reverse merger. There is no assurance that additional funding will be available.
The financial statements were prepared on a going-concern basis. The company had nominal assets, substantial liabilities relative to cash, no revenue, and cumulative losses since inception. Management identified the lack of funding and absence of a business combination as factors that may hinder continuation as a going concern.
Key structural risks include blank-check status, limited capital and management resources, potential dilution in a future combination, dependence on related parties, competition from better-funded acquisition vehicles, limited due diligence capability, and the possibility of completing only one highly concentrated business combination. The company had no material pending legal proceedings and no material off-balance-sheet arrangements.
During 2014, stockholders provided $15,000 of loans. Officers and directors received no compensation, and the company used management office space and equipment at no cost. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not required to provide an internal-control attestation.
Investor Verification Checklist
- Verify whether this filing belongs to Whitehawk Therapeutics, Inc. or to Zeta Acquisition Corp. II, as the source text names only the latter.
- Confirm the company’s legal name, ticker, current corporate status, and whether any subsequent business combination or reverse merger occurred.
- Review the going-concern disclosure and determine how the company funded operations after December 31, 2014.
- Confirm the terms, maturity, related-party status, and repayment history of the $125,000 stockholder notes and accrued interest.
- Assess potential dilution and changes in control associated with any future acquisition or reverse-merger transaction.
- Verify the reported share ownership, including the 80% ownership by the two officers and directors and the absence of a public trading market.